Legato Capital Management LLC Acquires 4,681 Shares of MediWound Ltd. (NASDAQ:MDWD)

Legato Capital Management LLC lifted its position in shares of MediWound Ltd. (NASDAQ:MDWD) by 12.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,753 shares of the biopharmaceutical company’s stock after purchasing an additional 4,681 shares during the period. Legato Capital Management LLC owned 0.41% of MediWound worth $779,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in MDWD. Investor AB bought a new position in shares of MediWound during the third quarter valued at about $15,750,000. Rosalind Advisors Inc. lifted its position in shares of MediWound by 22.3% during the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock valued at $11,343,000 after purchasing an additional 114,560 shares in the last quarter. ARK Investment Management LLC bought a new position in shares of MediWound during the third quarter valued at about $1,806,000. State Street Corp lifted its position in shares of MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after purchasing an additional 45,529 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of MediWound during the third quarter valued at about $212,000. 46.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of MediWound in a research report on Friday, January 10th.

MediWound Stock Performance

Shares of MDWD stock opened at $18.62 on Friday. The firm has a market cap of $200.84 million, a price-to-earnings ratio of -6.42 and a beta of 0.81. MediWound Ltd. has a 52 week low of $12.60 and a 52 week high of $24.00. The firm’s 50-day simple moving average is $18.04 and its two-hundred day simple moving average is $17.71.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the prior year, the business posted ($0.24) earnings per share. Analysts forecast that MediWound Ltd. will post -2.66 earnings per share for the current year.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.